Venous Thromboembolism Therapy with Edoxaban in Daily Care Patients: Results from the DRESDEN NOAC REGISTRY

Direct oral anticoagulants such as edoxaban are standard of care in current treatment of venous thromboembolism (VTE). However, phase III trial data need confirmation in real-world settings. We extracted data from the prospective, noninterventional multiple-indication DRESDEN NOAC REGISTRY to evaluate outcome rates during VTE treatment with edoxaban. Patients were included in this analysis, if they had acute VTE and if patient enrolment and edoxaban initiation occurred within 30 days after VTE diagnosis. Patient characteristics, treatment persistence, and clinical outcomes were centrally adjudicated using standard definitions. Until December 31, 2023, 323 acute VTE patients (median age 67 years, 56.7% male) were enrolled and initiated edoxaban within 7.8 ± 4.9 days (mean) for isolated deep vein thrombosis (DVT) (57.6%) or pulmonary embolism (PE) ± DVT (42.4%). Mean duration of follow-up was 3.9 ± 1.9 years with a mean duration of edoxaban exposure of 1.5 ± 1.7 years. During ongoing edoxaban therapy, 3/323 patients (0.9%) experienced recurrent VTE (0.6/100 patient-years); 141/323 (43.7%) patients reported clinically relevant International Society on Thrombosis and Haemostasis (ISTH) nonmajor bleeding and 16 reported ISTH major bleeding (5.0%; 3.2/100 patient-years). Death was observed in 53 patients (4.1/100 patient-years). At 6 months, 78.2% were still taking edoxaban, 2% were electively switched to dose-reduced secondary prophylaxis with apixaban 2.5 mg twice a day or rivaroxaban 10 mg once daily. The remaining patients had a scheduled end of VTE treatment (11.4%) or were switched to nonedoxaban therapeutic anticoagulation (6.2%). Our results indicate effectiveness of edoxaban in acute VTE treatment with excellent persistence in the treatment and low rates of unplanned discontinuation. Bleeding was frequently observed, but rates of major bleeding were low and comparable to phase III data.

Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.

El resumen se deja sin traducir para conservar la redacción original de los autores.

Registry data from 323 acute VTE patients on edoxaban showed effectiveness with low rates of recurrent VTE (0.9%) and major bleeding (5.0%), frequent nonmajor clinically relevant bleeding (43.7%), and 78.2% still on treatment at six months.

Explore cómo esta investigación se conecta con la práctica clínica

Más estudios revisados por pares en la categoría «Literatura clínica».

• Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Efectos de la hirudoterapia sobre las funciones hepáticas, el perfil lipídico y la sensibilidad a la insulina en ratas con síndrome metabólico — Bilden A et al. (2026)
• Eficacia y seguridad de la hirudoterapia para mejorar los parámetros de calidad espermática en la infertilidad masculina: un ensayo controlado aleatorizado — Abtahi-Forooshani M et al. (2026)
• Congestión venosa de un colgajo sural reverso manejada con éxito con enoxaparina en un paciente varón con lesión traumática por aplastamiento del pie: un caso clínico — Velasco-Bustamante J et al. (2026)
• Investigación de los efectos terapéuticos del tratamiento con sanguijuelas medicinales sobre la lesión por isquemia-reperfusión de la extremidad inferior — Ünal K et al. (2026)
• Eficacia de la terapia con sanguijuelas medicinales en diversas aplicaciones clínicas: un estudio exhaustivo de Azerbaiyán — Farzali S et al. (2025)
• Hirudoterapia en cirugía reconstructiva: casos clínicos y revisión — Heinz P et al. (2020)
• Hirudoterapia en la cicatrización de heridas — Nair H et al. (2022)
• Hirudoterapia para la isquemia de las extremidades en la unidad de cuidados intensivos pediátricos: una cohorte observacional retrospectiva — Resch J et al. (2022)

Ver toda la investigación analizada por la ASH →